Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.

IMPORTANCE Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.

[1]  R. Charles.  [The diagnosis and classification of diabetes mellitus]. , 1967, L' Infirmiere haitienne.

[2]  H. Siljander,et al.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial , 2008, The Lancet.

[3]  M. Knip,et al.  Prediction of Type 1 Diabetes in the General Population , 2010, Diabetes Care.

[4]  R. Pujol-Borrell,et al.  Reevaluation of Autoantibodies to Islet Cell Membrane in IDDM: Failure to Detect Islet Cell Surface Antibodies Using Human Islet Cells as Substrate , 1992, Diabetes.

[5]  E. Bonifacio,et al.  Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes , 2011, Diabetes Care.

[6]  E. Bonifacio,et al.  Brief Communication: Early Appearance of Islet Autoantibodies Predicts Childhood Type 1 Diabetes in Offspring of Diabetic Parents , 2004, Annals of Internal Medicine.

[7]  E. Bonifacio,et al.  Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. , 1999, Diabetes.

[8]  G. Puavilai,et al.  Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. , 1999, Diabetes research and clinical practice.

[9]  C. Mathieu,et al.  Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes , 2005, Diabetologia.

[10]  Jeffrey P. Krischer,et al.  Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 , 2009, Diabetes Care.

[11]  P. Bingley,et al.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. , 2004, Diabetes.

[12]  E. Gale.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes , 2004, The Lancet.

[13]  E. Bonifacio,et al.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes , 1990, The Lancet.

[14]  P. Bingley,et al.  Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk , 2006, Diabetologia.

[15]  M. Rewers,et al.  Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY) , 1996, Diabetologia.

[16]  A. Goday,et al.  PREDICTING INSULIN-DEPENDENT DIABETES , 1988, The Lancet.

[17]  K. Vehik,et al.  Long-Term Outcome of Individuals Treated With Oral Insulin , 2011, Diabetes Care.

[18]  L. Harrison,et al.  Islet autoimmunity in infants with a Type I diabetic relative is common but is frequently restricted to one autoantibody , 2000, Diabetologia.

[19]  E. Bonifacio,et al.  Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk , 2009, Diabetologia.

[20]  M. Rewers,et al.  Antiislet autoantibodies usually develop sequentially rather than simultaneously. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  P. Holland,et al.  The social and economic consequences of childhood‐onset Type 1 diabetes mellitus across the lifecourse: a systematic review , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[22]  G. Eisenbarth,et al.  Type I diabetes mellitus: a chronic autoimmune disease? , 1984, Pediatric clinics of North America.

[23]  J. Ilonen,et al.  Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  P. Bingley,et al.  IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. , 1998, Journal of immunology.

[25]  E. Bonifacio,et al.  Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. , 2004, Diabetes.

[26]  P. Bingley,et al.  Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies , 2012, Diabetes Care.

[27]  K. Vehik,et al.  Long-Term Outcome of Individuals Treated With Oral Insulin , 2011, Diabetes Care.